

"Gain Expertise with A-HSCT, or begin doing Allo HSCT...?"



Julia Palma MD
PINDA - Hospital Luis Calvo Mackenna



Ask yourself:

- **Is my transplant center ready to do quality HSCT? All types?**
- **Do I have the appropriate infrastructure?**



- **Do We have the right staff?**
- **Can we meet the international regulatory agencies requirements?**

Types of Transplants performed

- **Auto vs Allo**
- Matched sibling donor vs **alternative donors**
- Myeloablative vs **RIC**
- BM vs. PBSC vs. **Cord blood**
- Low risk patients vs **high risk patients**
- Non-malignant vs **malignant**



How many Transplants should do a Center?

NMDP and FACT:

10 allogeneic transplants per year

EBMT:

Total number of Allo performed: >200

Infrastructure

Cost and cost coverage of HSCT

Type of HSCT

Patients accepted for HSCT: low/high

Quality

Results (published)


No Relapse Mortality Total Mortality and Causes of Death

blood

2010 115: 3437-3446
Prepublished online December 29, 2009;
doi:10.1182/blood-2009-03-207010

Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group

Thomas Klingebiel, Jacqueline Cornish, Myriam Leblond, Franco Locatelli, Philippe Dasthous, Robert Handegardner, Adriana Bazzani, Joana Christo-Lima, Franca Fagioli, Heide G. Christina Peters, Franco Aversa, Emmanuelle Pösch, Giorgio Diot and VanOlson Rocha




Leukemia-free survival


blood 2010 115: 3437-3446
Prepublished online December 23, 2009;
doi:10.1182/blood-2009-03-207001

Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group

Thomas Klingebiel, Jacqueline Cornish, Myriam Lubijn, Franco Locatelli, Philippe Dabkephre, Robert Handgretinger, Adriana Bialuzzi, Joana Oriac-Lempach, Franca Fagioli, Reuven Or, Christina Peters, Franco Avanzi, Emmanuelle Pege, Giorgio Diot and Vanderson Rocha




PINDA – HLCM: HSCT Activity 1999-2012



263 HSCT: >200 Allogeneic

HSCT Activity 1999-2012



263HSCT: >200 Alogeneic

blood 2010 115: 3437-3446
 Published online December 29, 2009.
 doi:10.1182/blood-2009-03-220101

Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group

Thomas Klingebiel, Jacqueline Cornish, Wynant Luberg, Francis Locatelli, Philippe Daskalakis, Rupert Handgretinger, Adriana Eskudiz, Soeana Chiro-Larrosa, Franca Fagioli, Raulosa Cr., Christina Peters, Franco Aversa, Emmanuelle Polge, Giorgio Dihi and Vanderison Rocha

Autologous

Allogeneic

First Haplo transplant at HLCM

First CB transplant at HLCM

First Haplo transplant

First CB transplant

200 allogeneic transplants

**1999
BMTU CHILE
HLCM/PINDA**



SCT for cancer treatment


Allogeneic SCT in leukemia

Recognition of GvL

Successful MUD

CR with DLI

RIC



Costs

Pre
HSCT

HSCT

Post
HSCT